IMab (IMAB)
(Delayed Data from NSDQ)
$1.35 USD
+0.01 (0.75%)
Updated Oct 16, 2024 03:59 PM ET
After-Market: $1.32 -0.03 (-2.22%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.35 USD
+0.01 (0.75%)
Updated Oct 16, 2024 03:59 PM ET
After-Market: $1.32 -0.03 (-2.22%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Zacks News
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
IMab (IMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks
by Zacks Equity Research
IMab Sponsored ADR (IMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal
by Zacks Equity Research
I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.
I-Mab (IMAB) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
I-Mab (IMAB) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug
by Zacks Equity Research
The FDA raises concerns related to data in Reata's (RETA) NDA seeking approval for bardoxolone for treating Alport syndrome. An advisory committee meeting is scheduled tomorrow.
Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension
by Zacks Equity Research
Amryt (AMYT) is seeking approval for Oleogel-S10 for treating epidermolysis bullosa, a rare genetic skin disorder, in the United States and Europe. The FDA extends the review period for the drug's NDA to reviewnew data submission.
Does IMab Sponsored ADR (IMAB) Have the Potential to Rally 31% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for IMab Sponsored ADR (IMAB) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing
by Zacks Equity Research
Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.
3 Small Biotech Stocks in Focus on World Arthritis Day
by Indrajit Bandyopadhyay
Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.
AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy
by Zacks Equity Research
AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.
Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa
by Zacks Equity Research
Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.
Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension
by Zacks Equity Research
Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.
I-Mab (IMAB) Surges: Stock Moves 5.5% Higher
by Zacks Equity Research
I-Mab (IMAB) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Company News for Sep 8, 2020
by Zacks Equity Research
Companies in the news are: IMAB, LMPX, DPW, ANPC
AbbVie Partners With Chinese Biotech for Cancer Candidate
by Zacks Equity Research
AbbVie (ABBV) signs a collaboration agreement with China's I-Mab for developing/commercializing the latter's lemzoparlimab to address various cancer types.